March 19, 2018 10:30 AM EDT

Homology, Unum set IPO terms; Knight pays Ardelyx $19M for tenapanor rights in Canada

Amber Tong

→ Two biotechs in Boston have set the terms for their IPOs: Homology Medicines plans to raise $100 million by offering 6.7 million shares between …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Homology, Unum set IPO terms; Knight pays Ardelyx $19M for tenapanor rights in Canada

Amber Tong

Sign up to read this article for free.

A look at biotech's year of the megaround

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

Flagship biotech Valo Health ends 2024 with mid-stage fail

Ho­mol­o­gy, Unum set IPO terms; Knight pays Arde­lyx $19M for tena­panor rights in Cana­da

Amber Tong

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

Homology, Unum set IPO terms; Knight pays Ardelyx $19M for tenapanor rights in Canada

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

Flagship biotech Valo Health ends 2024 with mid-stage fail